Kairos Pharma (KAPA) Stock Price & Analysis Today

KAPA

(NYSEAMERICAN)

Kairos Pharma, Ltd.

$0.48-- (--)

Loading... - Market loading

Overview Financials Forecast Statistics Dividends Historical Profile

Kairos Pharma Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$0.47 - $0.52

52-Week High$2.11

52-Week Low$0.40

Open$0.47

Volume730.85K

Average Volume (3M)126.87K

Market Cap8.85M

Shares Outstanding18.43M

Price to Book (P/B)1.40

EV/EBITDA-0.83

50-Day MA$0.60

200-Day MA$0.88

52-Week Change-17.19%

Annual Dividend$0.00

Dividend Yield0.00%

Day's Range$0.47 - $0.52

52-Week High$2.11

52-Week Low$0.40

Open$0.47

Volume730.85K

Average Volume (3M)126.87K

Market Cap8.85M

Shares Outstanding18.43M

Price to Book (P/B)1.40

EV/EBITDA-0.83

50-Day MA$0.60

200-Day MA$0.88

52-Week Change-17.19%

Annual Dividend$0.00

Dividend Yield0.00%

About Kairos Pharma

Company overview, fundamentals, and corporate profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients.Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer.It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA.The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016.Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.

Frequently Asked Questions About Kairos Pharma

What is the current stock price for KAPA?

As of the latest trading session, KAPA stock trades at $0.48. The 52-week range is $0.40–$2.11, with a day range of $0.47–$0.52.

What is the P/E ratio for KAPA?

The P/E ratio (Price-to-Earnings) for KAPA is shown in the Key Statistics section. This valuation metric helps compare Kairos Pharma, Ltd. to industry peers.

Does KAPA pay dividends?

Kairos Pharma does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for KAPA?

Analyst ratings and recommendations for KAPA are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.

What is the market cap of KAPA?

Kairos Pharma's market capitalization is $8.8M, classifying it as a micro-cap company. Kairos Pharma operates in the Healthcare sector within the Biotechnology industry.

Kairos Pharma (KAPA) Stock Price & Financial Analysis

Kairos Pharma Stock Price Chart

Price Chart

Financial Metrics & Key Statistics

Frequently Asked Questions About Kairos Pharma